Literature DB >> 19498123

Protein C in critical illness.

Henry J Mann1, Mary A Short, Douglas E Schlichting.   

Abstract

PURPOSE: The role of protein C in critical illness is assessed.
SUMMARY: Conversion of protein C to activated protein C (APC) requires thrombin and thrombomodulin. When thrombin is not bound to thrombomodulin, it can convert fibrinogen to fibrin, factor V to factor Va, and factor VIII to factor VIIIa but will not convert protein C to APC. When thrombin is bound to thrombomodulin, it can convert protein C to APC but cannot convert fibrinogen, factor V, or factor VIII. Activation of protein C is accelerated by the presence of endothelial protein C receptors. In conjunction with protein S, APC limits coagulation by inactivating factors Va and VIIIa, which decreases thrombin-mediated inflammation. By inhibiting the formation of thrombin and the release of proinflammatory cytokines, APC reduces the inflammatory response to infection. By inducing cell signaling, APC directly modulates the cellular response to infection, resulting in antiinflammatory, cytoprotective, and barrier-protective activities. APC is metabolized by protease inhibitors and other proteins in the plasma. Conversion of protein C to APC is impaired in severe sepsis. During severe sepsis, endogenous levels of the inactive precursor protein C are reduced because of decreased production by the liver and degradation by enzymes. More than 85% of patients with severe sepsis have low levels of protein C. Absolute levels of protein C correlate with morbidity and mortality outcomes of the sepsis population, regardless of age, infecting microorganism, presence of shock, disseminated intravascular coagulation, degree of hypercoagulation, or severity of illness.
CONCLUSION: The protein C pathway is a natural homeostatic regulator with multiple mechanisms of action. Blood protein C concentration is inversely correlated with morbidity and mortality in sepsis and other critical illness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498123     DOI: 10.2146/ajhp080276

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

Review 1.  The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.

Authors:  Karen M Hook; Charles S Abrams
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

2.  [Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE)].

Authors:  F M Brunkhorst; V Patchev
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-29       Impact factor: 0.840

Review 3.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Parallel imaging of coagulation pathway proteases activated protein C, thrombin, and factor Xa in human plasma.

Authors:  Sylwia Modrzycka; Sonia Kołt; Stéphanie G I Polderdijk; Ty E Adams; Stanisław Potoczek; James A Huntington; Paulina Kasperkiewicz; Marcin Drąg
Journal:  Chem Sci       Date:  2022-04-27       Impact factor: 9.969

5.  Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.

Authors:  Xiao-Yan Zhao; Andreas Wilmen; Dongli Wang; Xinquan Wang; Maxine Bauzon; Ji-Yun Kim; Lars Linden; Liang Li; Ursula Egner; Tobias Marquardt; Dieter Moosmayer; Jan Tebbe; Julian Marius Glück; Philipp Ellinger; Kirk McLean; Shujun Yuan; Subramanian Yegneswaran; Xiaoqiao Jiang; Vince Evans; Jian-Ming Gu; Doug Schneider; Ying Zhu; Yifan Xu; Cornell Mallari; Ashley Hesslein; Yan Wang; Nicole Schmidt; Katrin Gutberlet; Christine Ruehl-Fehlert; Alexius Freyberger; Terry Hermiston; Chandra Patel; Derek Sim; Laurent O Mosnier; Volker Laux
Journal:  Nat Commun       Date:  2020-06-12       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.